IDYA News and Press, IDEAYA Biosciences Inc. From 09/08/25

IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer PR Newswire Overall response rate ( ORR ) of 57% (4/7; 3cPR+1uPR) in patients treated wi...

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma PR Newswire Treatment with darovasertib resulted in robust ocular tumor shrinkage, lower simulated radiation doses to the eye and meaningful visual ...

2025-09-08 05:15:37 ET U.S. stock futures edged up on Monday as investors looked ahead to two important inflation reports this week, that will shape expectations for the Federal Reserve's next move. ... Read the full article on Seeking Alpha For further details see:...

IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer PR Newswire 80.0% (8/10) ORR and 70.0% (7/10) confirmed ORR ...

2025-09-05 15:00:47 ET More on the markets U.S. Job Worries Intensify Calls For Immediate Fed Rate Cuts Tariffs Are Taxes: Ergo, Tax Cuts Are Coming Jobs Shock: 22K Hires, 4.3% Unemployment -- 50 Bps Is Now On The Table September Fed cut largely fully priced ...

2025-09-04 10:23:08 ET More on IDEAYA Biosciences IDEAYA Biosciences, Inc. (IDYA) Presents At Cantor Global Healthcare Conference 2025 Transcript Ideaya Biosciences: Moving Into ADCs For Solid Tumors IDEAYA Biosciences and Servier in-pact to develop eye cancer treatm...

2025-09-04 06:54:25 ET lvan Tuerkcan from JMP Securities issued a price target of $41.00 for IDYA on 2025-09-04 08:46:01. The adjusted price target was set to $41.00. At the time of the announcement, IDYA was trading at $25.76. The overall price target consensus is at $4...

IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer PR Newswire SOUTH SAN FRANCISCO, Calif. , Sept. 4, 2025 /PRNewswire...

2025-09-03 22:15:32 ET IDEAYA Biosciences, Inc. (IDYA) Cantor Global Healthcare Conference 2025 September 3, 2025 9:10 AM EDT... Read the full article on Seeking Alpha For further details see: IDEAYA Biosciences, Inc. (IDYA) Presents At Cantor Global Healthcare Conference 20...

IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors PR Newswire Dosing of first patient in Phase 1 dose escalation trial of IDE892 targeted in 4Q 2025 Preclinical profile of IDE892 and mechanistic...